Equities

Theriva Biologics Inc

Theriva Biologics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.80
  • Today's Change0.01 / 0.26%
  • Shares traded146.34k
  • 1 Year change-70.64%
  • Beta1.3886
Data delayed at least 15 minutes, as of Sep 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments234267
Total Receivables, Net1.940.230
Total Inventory------
Prepaid expenses2.293.501.53
Other current assets, total------
Total current assets274669
Property, plant & equipment, net22211.48
Goodwill, net5.705.53--
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets0.080.020.02
Total assets557270
LIABILITIES
Accounts payable0.770.920.52
Accrued expenses5.003.123.03
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.060.06--
Other current liabilities, total0.912.97--
Total current liabilities6.747.063.55
Total long term debt0.160.220
Total debt0.230.280
Deferred income tax01.62--
Minority interest----0
Other liabilities, total8.628.401.40
Total liabilities16174.96
SHAREHOLDERS EQUITY
Common stock0.020.020.13
Additional paid-in capital347344337
Retained earnings (accumulated deficit)(309)(291)(271)
Treasury stock - common(0.29)(0.29)--
Unrealized gain (loss)------
Other equity, total0.03(0.68)--
Total equity405565
Total liabilities & shareholders' equity557270
Total common shares outstanding171513
Treasury shares - common primary issue0.720.720.00
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.